Form 4: Precigen Director Acquires Shares, RSUs, Options

Precigen Director Steven Frank acquired common stock, restricted stock units, and stock options as part of his compensation.

Summary

• Steven Frank, a Director of Precigen, Inc. (PGEN), acquired various securities on March 10, 2026.
• Acquired 14,245 shares of common stock at a price of $3.51 per share, issued in lieu of an annual retainer of $50,000.
• Beneficial ownership of common stock following this transaction is 1,154,552 shares.
• Acquired 35,612 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Precigen common stock.
• The RSUs vest in full on March 10, 2027.
• Acquired 41,073 options to purchase common stock with an exercise price of $3.51 per share.
• These options are exercisable from March 10, 2026, and expire on March 10, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects a director's continued alignment with shareholder interests through equity compensation, a standard practice that reinforces long-term commitment.

Positives

• The director's compensation package includes a significant equity component, aligning his interests with those of shareholders.
• The acquisition of common stock, RSUs, and options demonstrates continued insider confidence in the company's future.

Future Outlook

The Restricted Stock Units are set to vest in full on March 10, 2027, and the acquired stock options have an exercise period extending until March 10, 2036, indicating long-term incentives for the director.

Management Comments

• The shares were issued to the reporting person in lieu of an annual retainer of $50,000.

Industry Context

StockSavvy.ai notes that providing equity-based compensation, such as common stock, restricted stock units, and stock options, to directors is a standard practice across many industries. This approach is widely adopted to align the financial interests of board members with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• Equity compensation for directors, including a mix of shares, RSUs, and options, is a common practice in the biotechnology and pharmaceutical sectors, similar to companies like Moderna or BioNTech, which frequently use such structures to incentivize leadership.
• The specific valuation of $3.51 per share for the common stock and options aligns with the market price at the time of grant, which is standard for such compensation packages.

Corporate Governance

Related Party Transactions

• The acquisition of common stock, restricted stock units, and stock options by Director Steven Frank from Precigen, Inc. constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity compensation structure aligns the director's interests with shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The Restricted Stock Units will vest on March 10, 2027.
• The stock options can be exercised at any time between March 10, 2026, and March 10, 2036.

Key Dates

Recommendation

This Form 4 details routine equity compensation for a director, which is a standard practice to align management interests with shareholders. It does not provide new fundamental information that would significantly alter an investment thesis or warrant a strong buy or sell recommendation based solely on this filing.

Keywords

Precigen, PGEN, Steven Frank, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Restricted Stock Units, Stock Options, Equity Compensation